Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (1y) (2011 - 2026)
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Cash from Operations Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 42.76% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 75.58% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 151.70% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 100.14% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 56.79% |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -103.71% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -103.71% |
| Mar 31, 2026 | -51.50% |
| Dec 31, 2025 | -1,518.99% |
| Sep 30, 2025 | -116.90% |
| Jun 30, 2025 | -120.15% |
| Mar 31, 2025 | -537.93% |
| Dec 31, 2024 | 51.31% |
| Sep 30, 2024 | -611.27% |
| Jun 30, 2024 | 47.59% |
| Mar 31, 2024 | -76.20% |
| Dec 31, 2023 | -139.63% |
| Sep 30, 2023 | -115.97% |
| Jun 30, 2023 | -332.54% |
| Mar 31, 2023 | 686.04% |
| Dec 31, 2022 | -64.61% |
| Sep 30, 2022 | 36.61% |
| Jun 30, 2022 | -70.11% |
| Mar 31, 2022 | -55.99% |
| Dec 31, 2021 | 37.85% |
| Sep 30, 2021 | 0.25% |